Regulatory Information Management (RIM): Foundations for Multi-Region Submissions

When the Spreadsheet Stops Working

A single regulatory submission can be tracked in a spreadsheet. Two or three can be tracked in a spreadsheet. Once a manufacturer is filing in five or more regions — FDA, EU MDR, MFDS, PMDA, NMPA — the spreadsheet starts to lose. Specific failure modes:

1. Document version mismatch. The same biocompatibility report is referenced in submissions to four regulators, but each submission has its own "current version" because the regulator's review timeline differs. The spreadsheet cannot show which version is in front of which reviewer.

2. Commitments tracking. A response to an FDA RAI commits to a labeling change. The EU file is silent. The MFDS file references the old version. Six months later nobody remembers what was committed to whom.

3. Renewal calendars overlap with submissions. A KGMP surveillance audit, a Korean license renewal, an FDA 510(k) supplement, and a new EU MDR submission all hit in the same quarter. Resources are not planned for the overlap.

4. Geographic submission status is not visible to commercial teams. Sales asks "when is the device available in Brazil?" and regulatory takes three days to answer because the spreadsheet does not have a portfolio-level view.

Regulatory Information Management (RIM) is the discipline of managing the regulatory portfolio as a structured asset rather than as a folder of submissions. For multi-region manufacturers, it is foundational infrastructure.

What a RIM System Actually Does

A RIM platform — Veeva Vault RIM, ArisGlobal LifeSphere, ENNOV, or a well-designed custom system — holds four core data sets and the relationships between them.

Set 1: Product Master

The canonical list of devices, variants, configurations, and SKUs. Each entry has classification per region, intended use phrasing per region, and the master technical file structure. When the same device classifies differently in different markets, the RIM holds the per-region position.

Set 2: Submissions Ledger

Every submission, RAI, response, approval, rejection, and renewal, with dates, regulator, status, and outcome. The submissions ledger is the regulatory history. Auditors and acquirers want to see this ledger; sales teams want to query it for "what is approved where."

Set 3: Document Repository

Authoritative versions of every regulatory document — technical files, IFUs, labels, summaries, clinical evidence, biocompatibility reports — with full version history and signed approval workflows. The repository is the source of truth that submissions reference.

Set 4: Commitments and Obligations

Every commitment made to a regulator (post-approval studies, labeling changes promised, vigilance enhancements) and every standing obligation (renewals, surveillance audits, annual reports). The commitments set is what keeps the regulatory team out of trouble between submissions.

The relationships between these sets are where the value lives. Querying "what FDA-approved documents reference biocompatibility report v3.2, and which are due for renewal in the next 12 months?" should be one operation, not a manual reconciliation.

The Foundations Question

Most RIM rollouts fail at the foundations layer — the upstream regulatory strategy that determines what gets filed where, by when, and with what. Without strategic foundations:

• The RIM platform becomes a graveyard of historical submissions with no forward planning.
• Submissions are reactive (to commercial requests, to competitor moves, to regulatory pressure) rather than driven by a portfolio strategy.
• The CRO/consultant spend is high because each submission is treated as bespoke.

Strong foundations include:

1. Region-prioritization framework — explicit criteria for which regions are filed, in what sequence, with what evidence base. A new product launching globally typically does not file in 30 regions simultaneously; the priority sequence has to be deliberate.

2. Predicate/equivalence library — for 510(k) and MFDS comparator submissions, a maintained library of acceptable predicates and equivalents per product category. Without the library, every submission redoes the predicate search.

3. Technical file architecture — a master file structure that can be re-projected into FDA, EU, Korea, Japan, and China formats with limited rework per region. The architecture is set once at the design-controls stage, not retroactively.

4. Clinical evidence strategy — what clinical or performance data is collected, in what populations, with what regulatory destinations in mind. The Korean and Japanese requirements for local data are knowable in advance; the clinical plan should incorporate them.

Choosing the RIM Platform vs Building One

For medical device manufacturers, the build-vs-buy question on RIM platforms generally favors buy. Reasons:

• Validated platforms have FDA Part 11 compliance built in. Custom systems require validation work that often exceeds platform license cost.
• The submission format requirements (eCTD-equivalents for some regions, FHIR-aligned data for others) are moving targets. Platform vendors track these; in-house teams struggle to.
• Integration with adjacent systems (eQMS, PLM, document control) is increasingly off-the-shelf with major RIM platforms.

The exception: very small manufacturers (single product, two regions) for whom the platform license is disproportionate to the volume of regulatory activity. For these manufacturers, structured spreadsheets supplemented by a document repository can suffice until the third region.

Migration Pain Points

For manufacturers migrating from spreadsheet-and-folder RIM to a platform RIM, three migration pain points consistently appear:

1. Historical submission data is incomplete. The team did not record every detail of every old submission. Reconstructing the history to populate the platform takes 3–6 months of focused effort.

2. Document version provenance is unclear. Which version of the biocompatibility report was actually in the 2022 FDA submission? Without RIM, this is sometimes unknowable. Migration teams either reconstruct or accept gaps.

3. Workflow expectations differ. Spreadsheets allow ad hoc updates. Platforms enforce workflow. Regulatory team members who are accustomed to spreadsheet flexibility experience the platform as bureaucratic until they adapt.

Plan for 12 months from kick-off to confident operation on a new RIM platform. Earlier than that is optimistic.

How This Connects to Submissions and Strategy

RIM is downstream of regulatory strategy and upstream of submissions execution. It is the infrastructure that allows strategy to be executed consistently and submissions to be tracked as a portfolio.

A manufacturer with clean RIM is faster on every submission because the technical content, the predicate library, the commitments history, and the document versions are immediately retrievable. The 510(k) that takes the average manufacturer 12 weeks to prepare often takes the RIM-equipped manufacturer 6–8 weeks for the same product complexity.

Where Leanabl Plugs In

The Platform RIM service handles RIM platform selection, configuration, and migration for medical device manufacturers. For upstream regulatory strategy that shapes what the RIM will contain, Regulatory Foundations builds the region-prioritization and technical file architecture. Specific multi-region submission execution runs through the Submissions service.